CatalYm Announces Initial Data from Ongoing Phase 2a Trial E

Oral presentation highlights first data from the GDFATHER-2a trial demonstrating lasting and confirmed responses (as per RECIST criteria) following treatment with visugromab and the anti-PD-1 inhibitor

Related Keywords

Zeiten , Mecklenburg Vorpommern , Germany , Chicago , Illinois , United States , American , Phil Lhuilier , Ignacio Melero Bermejo , Phil Lhuillier , Stefan Klotter , Catalym Gmb , International Coordinating Investigator Prof , American Society Of Clinical Oncology , Trophic Communications , Ted Human Effector Cell Relocation Phase , American Society , Clinical Oncology , Annual Meeting , Growth Differentiation , Eugen Leo , Chief Medical Officer , International Coordinating Investigator , Universidad De Navarra , Phill Huillier , Chief Executive Officer , Phill Huilier , Stephanie May , Stabile Ertr , Chart Profi Stefan Klotter , Blue Chips , Catalym , Nnounces , Nitial , Data , Rom , Ngoing , Hase , Trial , Valuating , Targeting , Ntibody , Isugromab , Combination , Nivolumab , Disco , 023 ,